Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MPI | P34949 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5676 | 0.82 | — | — | |
| SCHEMBL244401 | 0.78 | — | — | |
| Hydrogen Sulfide SCHEMBL27838627 | 0.78 | — | — | |
| Carbamic Acid SCHEMBL285340 | 0.76 | NAPRT (0.50) | NAPRTP2RX7KDM4EL3MBTL1 | |
| Bicarbonate SCHEMBL2178826 | 0.74 | NAPRT (0.48) | NAPRTP2RX7KDM4EL3MBTL1 | |
| Pyrimidine SCHEMBL28189823 | 0.69 | CYP2A6 (0.33) | HSP90AA1NOS3NOS1NOS2PI4KA | |
| Quinoline SCHEMBL9545612 | 0.64 | ALDH1A1 (0.74) | HSP90AA1NOS2KDM4E | |
| Pyrimidine SCHEMBL1277018 | 0.61 | TSHR (0.33) | NAPRT | |
| Benzene SCHEMBL27835420 | 0.60 | TP53 (0.30) | — | |
| SCHEMBL3667891 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1198589-B9 | TENASCIN-C NUCLEIC ACID LIGANDS | GILEAD SCIENCES INC (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1203007-B1 | NUCLEIC ACID LIGANDS TO HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR (HGF/SF) AND ITS RECEPTOR C-MET | GILEAD SCIENCES INC (US) | 2009-04-15 | — | — | EP | disclosed |
| EP-1198589-B1 | TENASCIN-C NUCLEIC ACID LIGANDS | GILEAD SCIENCES INC (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20060105378-A1 | Tenascin-C nucleic acid ligands | GILEAD SCIENCES, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-7005260-B1 | Tenascin-C nucleic acid ligands | GILEAD SCIENCES, INC. (US) | 2006-02-28 | — | — | US | disclosed |
| US-20040058884-A1 | Detecting diseases by Selex method; anticancer agents | GILEAD SCIENCES, INC. | 2004-03-25 | — | — | US | disclosed |
| US-6596491-B2 | Included are specific RNA ligands to tenascin-C identified by SELEX; diagnosis and treatment of cancer, psoriasis, and atherosclerosis. | GILEAD SCIENCES, INC. | 2003-07-22 | — | — | US | disclosed |
| US-20030104377-A1 | Included are specific RNA ligands to tenascin-C identified by SELEX; diagnosis and treatment of cancer, psoriasis, and atherosclerosis. | GILEAD SCIENCES, INC. | 2003-06-05 | — | — | US | disclosed |
| EP-1203007-A4 | NUCLEIC ACID LIGANDS TO HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR (HGF/SF) OR ITS RECEPTOR C-MET AND TO INTEGRINS | GILEAD SCIENCES INC (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1198589-A4 | TENASCIN-C NUCLEIC ACID LIGANDS | GILEAD SCIENCES INC (US) | 2003-02-19 | — | — | EP | disclosed |
| EP-1203007-A1 | NUCLEIC ACID LIGANDS TO HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR (HGF/SF) OR ITS RECEPTOR C-MET AND TO INTEGRINS | GILEAD SCIENCES, INC. (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1198589-A1 | TENASCIN-C NUCLEIC ACID LIGANDS | GILEAD SCIENCES, INC. (US) | 2002-04-24 | — | — | EP | disclosed |
| US-6232071-B1 | AMPLIFYING INCREASED AFFINITY NUCLEIC ACIDS; CANCER DIAGNOSIS | GILEAD SCIENCES, INC. | 2001-05-15 | — | — | US | disclosed |
| WO-2001009390-A1 | TENASCIN-C NUCLEIC ACID LIGANDS | GILEAD SCIENCES, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009159-A1 | NUCLEIC ACID LIGANDS TO HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR (HGF/SF) OR ITS RECEPTOR C-MET AND TO INTEGRINS | GILEAD SCIENCES, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030104377-A1 | Included are specific RNA ligands to tenascin-C identified by SELEX; diagnosis and treatment of cancer, psoriasis, and atherosclerosis. | CXCL10, TLR3, CCL2 | HSP90AA1 1263/4885NOS3 1207/4885NOS1 1316/4885 |
| US-20040058884-A1 | Detecting diseases by Selex method; anticancer agents | TLR3, HAVCR2, SNRPE | HSP90AA1 1297/4885NOS3 2591/4885NOS1 3134/4885 |
| US-20060105378-A1 | Tenascin-C nucleic acid ligands | TLR3, CXCL10, CCL2 | HSP90AA1 1264/4885NOS3 1896/4885NOS1 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.